ABCC4 polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5'-deoxy-5-fluorouridine in

Natsumi Matsumoto1,2, Ayano Oishi3, Shotaro Yoshino3

  • 1Department of Cancer Genome and Pharmacotherapy, Showa Medical University Graduate School of Pharmacy, Hatanodai, Shinagawa-ku, Tokyo, Japan.

Abstract